LISATA THERAPEUTICS I

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

22 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Present at BIO CEO & Investor Conference

20 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

17 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

04 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

12 ديسمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Present at NobleCon19 Investor Conference

28 نوفمبر 2023 16:05:03 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

09 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 نوفمبر 2023 16:05:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

26 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

24 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer 

17 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

28 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in InfoSec World 2023

20 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

12 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

06 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

05 سبتمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

14 أغسطس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

08 أغسطس 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

07 أغسطس 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

11 يوليو 2023 08:30:00 بحسب Nasdaq GlobeNewswire